“Patients remain our focus, and early execution on our clinical trials across disease areas is a testament to that commitment,” said Paul J. Hastings, CEO of Nkarta. “NKX019 has the potential to reach people living with a wide range of autoimmune diseases, and we will continue to evaluate ways to maximize our impact in this field. Our cellular engineering enables us to evaluate a reduced toxicity lymphodepletion regimen, to limit hospitalization and patient burden, and spare the complications of other agents.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NKTX:
- Correction: Nkarta Reports Second Quarter 2024 Financial Results and Corporate Highlights
- Nkarta Reports Second Quarter 2024 Financial Results and Corporate Highlights
- Nkarta’s (NKTX) Making Promising Progress in Its Clinical-Stage Journey
- Nkarta Announces Initiation of Investigator-Sponsored Clinical Trial Evaluating NKX019 for Systemic Lupus Erythematosus
- Nkarta initiates trial of NKX019 in lupus erythematosus
Questions or Comments about the article? Write to editor@tipranks.com